Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. IRT
7. QCOM
8. ASO
9. LAES
10. NTHI

Go back to Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Gilead Sciences (NASDAQ: GILD) Delayed: 145.73 -0.91 (0.62%)
Previous Close $146.64    52 Week High $108.63 
Open $145.46    52 Week Low $71.39 
Day High $147.68    P/E 80.51 
Day Low $145.00    EPS $1.81 
Volume 2,376,870